Pfizer stock sets November 3 earnings date after guidance raise
Published on 10/06/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer stock (ISIN US7170811035) was trading at USD 27.50 on the NYSE on October 6, 2026, up 0.31 percent from the prior close. The next major checkpoint is November 3, when Pfizer is scheduled to publish its third-quarter 2026 report after raising its full-year revenue outlook.
November 3 brings the next test
According to Pfizer in its September 22, 2026 release, the company will discuss its third-quarter performance with analysts on November 3, 2026, at 10:00 a.m. EST. The report will show whether the newer portfolio continues to offset pressure on COVID products and older franchises.
That question follows a stronger second quarter. Financial Report Insights said Q2 2026 revenue rose 2.6 percent year over year to USD 15.034 billion from USD 14.653 billion, while adjusted diluted EPS was USD 0.77 compared with USD 0.78 in the year-ago quarter.
Guidance improves while earnings lag
Vermoegenszentrum reported on October 5, 2026 that management lifted full-year 2026 revenue guidance to USD 60.5 billion-USD 62.5 billion from USD 59.5 billion-USD 60.5 billion. The midpoint therefore increased by USD 500 million, while adjusted diluted EPS guidance stayed at USD 2.80-USD 3.00.
The accounting picture remains more uneven than the adjusted figures. Pfizer reported a Q2 GAAP loss of USD 0.04 per diluted share after USD 4.3 billion of non-cash intangible impairments, while adjusted diluted EPS remained positive at USD 0.77, according to Vermoegenszentrum. For investors, the November report must show whether revenue growth is translating into earnings after these charges.
Consensus leaves limited room
MarketBeat reported on October 5, 2026 that 21 analysts held a consensus rating of Hold and an average price target of USD 28.39. HSBC raised its target from USD 28.00 to USD 30.00 on September 10, 2026, while BMO Capital Markets cut its target from USD 34.00 to USD 30.00 on July 13, 2026.
At USD 27.50, the average consensus target is 3.2 percent above the intraday price. Pfizer's 52-week range is USD 23.62 to USD 29.21, placing the stock 5.9 percent below its yearly high.
Pfizer stock stays below its yearly high
Pfizer stock was last at USD 27.50 on the NYSE on October 6, 2026, with volume of 6,660,822 shares and a market capitalization of USD 156.7 billion.
Pfizer stock key data
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Trading venue: NYSE
- Price (as of October 6, 2026, 11:24 a.m. ET): USD 27.50
- Market capitalization: USD 156.7 billion (as of October 6, 2026)
- 52-week range: USD 23.62-29.21 (as of October 6, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
Upcoming dates for Pfizer stock
- November 3, 2026: Third-quarter 2026 performance report and analyst webcast
